Celldex Therapeutics (CLDX) Other Gross PP&E Adjustments (2016 - 2025)
Celldex Therapeutics (CLDX) has 15 years of Other Gross PP&E Adjustments data on record, last reported at $25.3 million in Q4 2025.
- For Q4 2025, Other Gross PP&E Adjustments rose 752.09% year-over-year to $25.3 million; the TTM value through Dec 2025 reached $25.3 million, up 752.09%, while the annual FY2025 figure was $25.3 million, 752.09% up from the prior year.
- Other Gross PP&E Adjustments reached $25.3 million in Q4 2025 per CLDX's latest filing, up from -$2.7 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $25.3 million in Q4 2025 and bottomed at -$3.9 million in Q2 2022.
- Average Other Gross PP&E Adjustments over 5 years is $1.7 million, with a median of -$2.8 million recorded in 2021.
- Peak YoY movement for Other Gross PP&E Adjustments: tumbled 67.69% in 2024, then skyrocketed 752.09% in 2025.
- A 5-year view of Other Gross PP&E Adjustments shows it stood at $20.8 million in 2021, then fell by 1.07% to $20.6 million in 2022, then crashed by 55.37% to $9.2 million in 2023, then crashed by 67.69% to $3.0 million in 2024, then surged by 752.09% to $25.3 million in 2025.
- Per Business Quant database, its latest 3 readings for Other Gross PP&E Adjustments were $25.3 million in Q4 2025, -$2.7 million in Q3 2025, and -$3.1 million in Q2 2025.